Compugen Ltd

Research Compugen Ltd (CGEN) on Bullrun: valuation model: 108.7% undervalued, market cap USD 204.23M, P/E 5.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCGEN
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal108.7% undervalued
• Market capUSD 204.23M
• P/E5.9
• Financial periodFY2025
• RevenueUSD 72.76M
• Revenue growth161.1%
• Net incomeUSD 35.34M
• Free cash flowUSD 31.33M
• Gross margin87.3%

Valuation Snapshot

Bullrun's latest valuation model marks Compugen Ltd as 108.7% undervalued; latest market cap is USD 204.23M; P/E is 5.9.

About Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody;

Frequently asked questions

Is Compugen Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Compugen Ltd as 108.7% undervalued.

What is Compugen Ltd's market cap?

Compugen Ltd's market capitalization is USD 204.23M.

What is Compugen Ltd's P/E ratio?

Compugen Ltd's price-to-earnings (P/E) ratio is 5.9.

What does Compugen Ltd do?

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.